Compare Autodesk Inc (ADSK) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Bristol-Myers Squibb Co — how do they compare? Autodesk Inc trades at $208.54 (market cap $44.84B), while Bristol-Myers Squibb Co trades at $57.94 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.6× Autodesk Inc's market cap, and Bristol-Myers Squibb Co pays a 4.35% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | BMY | |
|---|---|---|
Market Cap | $44.84B | $118.38B |
Sector | Technology | Health |
52-Week High | $326.79 | $62.37 |
52-Week Low | $187.72 | $42.60 |
Enterprise Value | $44.64B | $154.32B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
